Acthar Gel in FSGS

FSGS is a rare disease caused by the scarring of sections of your kidneys (glomeruli). Each kidney is made up of several glomeruli that aid the body in filtering waste products from the blood. This waste is removed from the body in the form of urine. When the glomeruli become scarred, the filtering mechanism does not work correctly resulting in the leakage of protein into the urine. H.P. Acthar Gel (repository corticotrophin injection), the study medication, is approved by the FDA and used to treat patients with proteinuria. It is a medication that is injected under the skin. Proteinuria is when the kidneys allow an excess amount of protein that is normally found in the blood to escape in the urine. The purpose of this study is to examine the effects of this study medication for FSGS. Your participation in this study could last about 16 months (65 weeks). If you are eligible for study participation, you will be expected to return to the study doctor’s office for a total of approximately 16 visits.